Clinical trial
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting…
NCT00219908 · Rennes University Hospital, Other · Terminated
Key facts
| NCT number | NCT00219908 |
|---|---|
| Title | Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis |
| Official title | Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: Induction Treatment With Mitoxantrone Followed by Long-Term Treatment With Interferon-beta1b |
| Lead sponsor | Rennes University Hospital, Other |
| Collaborators | Bayer Industry Wyeth is now a wholly owned subsidiary of Pfizer Farmades, Italy |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Mitoxantrone |
| Enrollment | 124 |
| Start date | Jul 1, 1999 |
| Completion | Jun 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 22, 2005 |
| Countries | France, Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: